Geron Corporation

1.39-0.0800-5.44%Vol 1.14M1Y Perf 15.84%
Apr 19th, 2021 12:45 DELAYED
BID1.39 ASK1.40
Open1.45 Previous Close1.47
Pre-Market1.47 After-Market-
 - -%  - -
Target Price
4.50 
Analyst Rating
Strong Buy 1.00
Potential %
223.74 
Finscreener Ranking
★★★★     54.42
Insiders Trans % 3/6/12 mo.
-/-/100 
Value Ranking
★★★+     53.97
Insiders Value % 3/6/12 mo.
-/-/100 
Growth Ranking
★★+     51.26
Insiders Shares Cnt. % 3/6/12 mo.
-/-/100 
Income Ranking
 —    -
Market Cap442.76M 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
22.31 
Earnings Date
27th May 2021

Today's Price Range

1.381.47

52W Range

1.102.40

5 Year PE Ratio Range

-9.2017.56K

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-0.68%
1 Month
-18.78%
3 Months
-10.91%
6 Months
-23.83%
1 Year
15.84%
3 Years
-63.16%
5 Years
-54.91%
10 Years
-70.72%

TickerPriceChg.Chg.%
GERN1.39-0.0800-5.44
AAPL133.77-0.3900-0.29
GOOG2 288.85-8.9100-0.39
MSFT258.03-2.7100-1.04
XOM56.11-0.5500-0.97
WFC43.870.03000.07
JNJ162.600.36000.22
FB300.81-5.3700-1.75
GE13.33-0.0600-0.45
JPM152.89-0.4100-0.27
Financial StrengthValueIndustryS&P 500US Markets
6.40
6.50
0.12
0.14
-98.50
Leverage Ratio 1.20
ProfitabilityValueIndustryS&P 500US Markets
-
-29 587.70
-29 218.20
-10 085.00
-
RevenueValueIndustryS&P 500US Markets
201.00K
0.00
-35.99
-60.66
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.06-0.07-16.67
Q03 2020-0.05-0.06-20.00
Q02 2020-0.07-0.0614.29
Q01 2020-0.09-0.0811.11
Q04 2019-0.20-0.1525.00
Q03 2019-0.14-0.0842.86
Q02 2019-0.06-0.08-33.33
Q01 2019-0.06-0.0516.67
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.08-14.29Negative
6/2021 QR-0.08-14.29Negative
12/2021 FY-0.35-16.67Negative
12/2022 FY-0.34-13.33Negative
Next Report Date27th May 2021
Estimated EPS Next Report-0.08
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume1.14M
Shares Outstanding318.53M
Trades Count2.92K
Dollar Volume8.61M
Avg. Volume3.64M
Avg. Weekly Volume1.94M
Avg. Monthly Volume2.27M
Avg. Quarterly Volume3.82M

Geron Corporation (NASDAQ: GERN) stock closed at 1.47 per share at the end of the most recent trading day (a -2.65% change compared to the prior day closing price) with a volume of 1.68M shares and market capitalization of 442.76M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 46 people. Geron Corporation CEO is John A. Scarlett.

The one-year performance of Geron Corporation stock is 15.84%, while year-to-date (YTD) performance is -7.55%. GERN stock has a five-year performance of -54.91%. Its 52-week range is between 1.1 and 2.4, which gives GERN stock a 52-week price range ratio of 22.31%

Geron Corporation currently has a PE ratio of -5.40, a price-to-book (PB) ratio of 2.30, a price-to-sale (PS) ratio of 2 250.32, a price to cashflow ratio of 41.10, a PEG ratio of 2.32, a ROA of -33.54%, a ROC of -37.63% and a ROE of -42.23%. The company’s profit margin is -%, its EBITDA margin is -29 218.20%, and its revenue ttm is $201.00 Thousand , which makes it $0.00 revenue per share.

Of the last four earnings reports from Geron Corporation, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.08 for the next earnings report. Geron Corporation’s next earnings report date is 27th May 2021.

The consensus rating of Wall Street analysts for Geron Corporation is Strong Buy (1), with a target price of $4.5, which is +223.74% compared to the current price. The earnings rating for Geron Corporation stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Geron Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Geron Corporation has a Sell technical analysis rating based on Technical Indicators (ADX : 20.60, ATR14 : 0.11, CCI20 : -88.26, Chaikin Money Flow : -0.18, MACD : -0.10, Money Flow Index : 29.33, ROC : -3.29, RSI : 50.24, STOCH (14,3) : 33.33, STOCH RSI : 0.64, UO : 43.00, Williams %R : -66.67), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Geron Corporation in the last 12-months were: Elizabeth G. O¿Farrell (Buy at a value of $60 346)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (100.00 %)
4 (100.00 %)
3 (75.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
1 (25.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.25

Geron Corporation

Geron Corp is a clinical stage biopharmaceutical company focused on research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses the global rights to this drug.

CEO: John A. Scarlett

Telephone: +1 650 473-7700

Address: 149 Commonwealth Drive, Menlo Park 94025, CA, US

Number of employees: 46

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

52%48%

Bearish Bullish

52%48%

Bearish Bullish

48%52%

News

Stocktwits